Sophiris Bio Inc (SPHS) - Financial and Strategic SWOT Analysis Review
![](/report_cover/1896/sophiris_bio_inc_shs_financial_n_strategic_swot_analysis_review_en.gif)
Sophiris Bio Inc (SPHS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
Sophiris Bio Inc (Sophiris) is a biopharmaceutical company that focuses on the research and development of products for treating urological diseases. The company’s lead pipeline product is Topsalysin (PRX302), which is being developed for the treatment of localized low to intermediate prostate cancer, as well as for the treatment of lower urinary tract symptoms of enlarged prostate or benign prostatic hyperplasia (BPH). It is a modified recombinant protein that is delivered through ultrasound-guided injection directly into the prostate. The company primarily operates in the US and has collaboration and license agreements with UVIC Industry Partnerships Inc, The Johns Hopkins University and Kissei Pharmaceutical Co., Ltd for the development and commercialization of its pipeline product. Sophiris is headquartered in La Jolla, California, the US.
Sophiris Bio Inc Key Recent Developments
May 18,2020: Sophiris Bio to shut down operations
Mar 10,2020: Sophiris Bio announces Nasdaq delisting
Nov 07,2019: Sophiris Bio reports third quarter 2019 financial results and recent corporate highlights
Aug 09,2019: Sophiris Bio reports second quarter 2019 financial results and recent corporate highlights
May 09,2019: Sophiris Bio reports first quarter 2019 financial results
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Sophiris Bio Inc (Sophiris) is a biopharmaceutical company that focuses on the research and development of products for treating urological diseases. The company’s lead pipeline product is Topsalysin (PRX302), which is being developed for the treatment of localized low to intermediate prostate cancer, as well as for the treatment of lower urinary tract symptoms of enlarged prostate or benign prostatic hyperplasia (BPH). It is a modified recombinant protein that is delivered through ultrasound-guided injection directly into the prostate. The company primarily operates in the US and has collaboration and license agreements with UVIC Industry Partnerships Inc, The Johns Hopkins University and Kissei Pharmaceutical Co., Ltd for the development and commercialization of its pipeline product. Sophiris is headquartered in La Jolla, California, the US.
Sophiris Bio Inc Key Recent Developments
May 18,2020: Sophiris Bio to shut down operations
Mar 10,2020: Sophiris Bio announces Nasdaq delisting
Nov 07,2019: Sophiris Bio reports third quarter 2019 financial results and recent corporate highlights
Aug 09,2019: Sophiris Bio reports second quarter 2019 financial results and recent corporate highlights
May 09,2019: Sophiris Bio reports first quarter 2019 financial results
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
SECTION 1 - ABOUT THE COMPANY
Sophiris Bio Inc - Key Facts
Sophiris Bio Inc - Key Employees
Sophiris Bio Inc - Key Employee Biographies
Sophiris Bio Inc - Major Products and Services
Sophiris Bio Inc - History
Sophiris Bio Inc - Company Statement
Sophiris Bio Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
SECTION 2 – COMPANY ANALYSIS
Company Overview
Sophiris Bio Inc - Business Description
Sophiris Bio Inc - SWOT Analysis
SWOT Analysis - Overview
Sophiris Bio Inc - Strengths
Sophiris Bio Inc - Weaknesses
Sophiris Bio Inc - Opportunities
Sophiris Bio Inc - Threats
Sophiris Bio Inc - Key Competitors
SECTION 3 – COMPANY FINANCIAL RATIOS
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES
Sophiris Bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Sophiris Bio Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Sophiris Bio Inc, Recent Deals Summary
SECTION 5 – COMPANY’S RECENT DEVELOPMENTS
May 18, 2020: Sophiris Bio to shut down operations
Mar 10, 2020: Sophiris Bio announces Nasdaq delisting
Nov 07, 2019: Sophiris Bio reports third quarter 2019 financial results and recent corporate highlights
Aug 09, 2019: Sophiris Bio reports second quarter 2019 financial results and recent corporate highlights
May 09, 2019: Sophiris Bio reports first quarter 2019 financial results
Mar 13, 2019: Sophiris Bio reports fourth quarter 2018 and year-end financial results and recent corporate highlights
SECTION 6 – APPENDIX
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
Sophiris Bio Inc - Key Facts
Sophiris Bio Inc - Key Employees
Sophiris Bio Inc - Key Employee Biographies
Sophiris Bio Inc - Major Products and Services
Sophiris Bio Inc - History
Sophiris Bio Inc - Company Statement
Sophiris Bio Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
SECTION 2 – COMPANY ANALYSIS
Company Overview
Sophiris Bio Inc - Business Description
Sophiris Bio Inc - SWOT Analysis
SWOT Analysis - Overview
Sophiris Bio Inc - Strengths
Sophiris Bio Inc - Weaknesses
Sophiris Bio Inc - Opportunities
Sophiris Bio Inc - Threats
Sophiris Bio Inc - Key Competitors
SECTION 3 – COMPANY FINANCIAL RATIOS
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES
Sophiris Bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Sophiris Bio Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Sophiris Bio Inc, Recent Deals Summary
SECTION 5 – COMPANY’S RECENT DEVELOPMENTS
May 18, 2020: Sophiris Bio to shut down operations
Mar 10, 2020: Sophiris Bio announces Nasdaq delisting
Nov 07, 2019: Sophiris Bio reports third quarter 2019 financial results and recent corporate highlights
Aug 09, 2019: Sophiris Bio reports second quarter 2019 financial results and recent corporate highlights
May 09, 2019: Sophiris Bio reports first quarter 2019 financial results
Mar 13, 2019: Sophiris Bio reports fourth quarter 2018 and year-end financial results and recent corporate highlights
SECTION 6 – APPENDIX
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
LIST OF TABLES
Sophiris Bio Inc, Key Facts
Sophiris Bio Inc, Key Employees
Sophiris Bio Inc, Key Employee Biographies
Sophiris Bio Inc, Major Products and Services
Sophiris Bio Inc, History
Sophiris Bio Inc, Subsidiaries
Sophiris Bio Inc, Key Competitors
Sophiris Bio Inc, Ratios based on current share price
Sophiris Bio Inc, Annual Ratios
Sophiris Bio Inc, Annual Ratios (Cont...1)
Sophiris Bio Inc, Interim Ratios
Sophiris Bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Sophiris Bio Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Sophiris Bio Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
Sophiris Bio Inc, Key Facts
Sophiris Bio Inc, Key Employees
Sophiris Bio Inc, Key Employee Biographies
Sophiris Bio Inc, Major Products and Services
Sophiris Bio Inc, History
Sophiris Bio Inc, Subsidiaries
Sophiris Bio Inc, Key Competitors
Sophiris Bio Inc, Ratios based on current share price
Sophiris Bio Inc, Annual Ratios
Sophiris Bio Inc, Annual Ratios (Cont...1)
Sophiris Bio Inc, Interim Ratios
Sophiris Bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Sophiris Bio Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Sophiris Bio Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
LIST OF FIGURES
Sophiris Bio Inc, Performance Chart (2014 - 2018)
Sophiris Bio Inc, Ratio Charts
Sophiris Bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Sophiris Bio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020
COMPANIES MENTIONED
Procept Biorobotics Inc
Pfizer Inc
Nymox Pharmaceutical Corp
NXThera Inc
Lipocine Inc
Light Sciences Oncology Inc
Astellas Pharma US Inc
Allergan Finance LLC
Sophiris Bio Inc, Performance Chart (2014 - 2018)
Sophiris Bio Inc, Ratio Charts
Sophiris Bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Sophiris Bio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020
COMPANIES MENTIONED
Procept Biorobotics Inc
Pfizer Inc
Nymox Pharmaceutical Corp
NXThera Inc
Lipocine Inc
Light Sciences Oncology Inc
Astellas Pharma US Inc
Allergan Finance LLC